MARKET

CORT

CORT

Corcept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.50
-0.26
-1.52%
After Hours: 16.50 +0.01 +0.03% 16:41 07/10 EDT
OPEN
16.74
PREV CLOSE
16.75
HIGH
16.83
LOW
16.37
VOLUME
566.57K
TURNOVER
--
52 WEEK HIGH
18.53
52 WEEK LOW
9.70
MARKET CAP
1.89B
P/E (TTM)
19.02
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CORT stock price target is 16.75 with a high estimate of 26.00 and a low estimate of 7.00.

EPS

CORT News

More
These 3 Biotech Stocks Are Outperforming Their Peers Here's Why
Investor's Business Daily · 5d ago
Is Corcept Therapeutics Incorporated's(NASDAQ:CORT) Recent Stock Performance Tethered To Its Strong Fundamentals?
Simply Wall St. · 6d ago
Corcept's Phase 3 Trial, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/05 10:40
Corcept Therapeutics initiates late-study for Relacorilant doublet therapy in pancreatic cancer
Seeking Alpha - Article · 07/01 16:02
Corcept launches late-stage study of relacorilant in pancreatic cancer
Seeking Alpha - Article · 07/01 16:02
Corcept Begins Enrollment in Phase III Pancreatic Cancer Study
Zacks · 07/01 15:47
Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
GlobeNewswire · 06/30 21:05
Corcept Therapeutics Reports Initiation Of Phase 3 Trial Of Relacorilant Plus Nab-Paclitaxel In Patients with Metastatic Pancreatic Cancer
Benzinga · 06/30 20:08

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About CORT

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.
More

Webull offers kinds of Corcept Therapeutics Incorporated stock information, including NASDAQ:CORT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CORT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CORT stock methods without spending real money on the virtual paper trading platform.